Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review.

Cancers·2026
Same author

A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'".

Dermatology and therapy·2026
Same author

Dose-Response and survival analysis after transarterial radioembolization for intrahepatic cholangiocarcinoma: A multicenter multicompartment dosimetry study.

European journal of nuclear medicine and molecular imaging·2026
Same author

Real-world outcomes of [<sup>177</sup>Lu]Lu-PSMA-I&T in [<sup>18</sup>F]FDG-positive metastatic castration-resistant prostate cancer: factors related to response and survival.

European journal of nuclear medicine and molecular imaging·2026
Same author

Dual tracer PET/CT imaging for a patient with lipoadenoma: what Choline missed but Trivehexin revealed.

European journal of nuclear medicine and molecular imaging·2026
Same author

Addressing respiratory gating latency for accurate pulse delivery in preclinical electron FLASH irradiation on a clinical linear accelerator.

ArXiv·2026

Related Experiment Video

Updated: Jun 17, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Pretest PSA and Restaging PSMA PET/CT Predict Survival in Biochemically Recurrent Prostate Cancer.

Rie von Eyben1, Manuela Andrea Hoffmann2,3, Cigdem Soydal4

  • 1Cytel Incorporated, Waltam, MA 02452, USA.

Biomedicines
|September 28, 2023
PubMed
Summary

A new risk model using prostate specific antigen (PSA) and PSMA PET/CT imaging accurately predicts overall survival in patients with biochemical recurrence (BCR). This model aids in better patient management and future clinical trials.

Keywords:
Cox regression analysis of survivalprostate specific antigen (PSA) relapseprostate specific membrane antigen (PSMA) PET/CTrestaging

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.8K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

270

Related Experiment Videos

Last Updated: Jun 17, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K
Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.8K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

270

Area of Science:

  • Oncology
  • Radiology
  • Prognostic Modeling

Background:

  • Biochemical recurrence (BCR) risk stratification is crucial for prostate cancer management.
  • Existing models may not fully capture prognostic information.
  • Novel approaches incorporating advanced imaging are needed.

Purpose of the Study:

  • To develop and validate a risk model for overall survival (OS) in BCR patients.
  • To assess the combined utility of pretest prostate specific antigen (PSA) and restaging prostate specific membrane antigen (PSMA) PET/CT.
  • To identify key predictors of OS in BCR.

Main Methods:

  • A cohort of 1216 BCR patients was analyzed.
  • Overall survival (OS) was evaluated based on PSA thresholds and PSMA PET/CT findings.
  • Cox regression analysis identified significant predictors of OS.

Main Results:

  • Four variables significantly predicted OS: treatment center, ISUP grade, pretest PSA, and number of positive sites on PSMA PET/CT.
  • Higher PSA values and more positive sites on PSMA PET/CT correlated with poorer OS.
  • 11% of patients died, with mortality rates increasing with higher PSA and more positive PSMA PET/CT findings.

Conclusions:

  • Pretest PSA and PSMA PET/CT are critical determinants of OS in BCR patients.
  • The developed risk model shows promise for clinical application.
  • Findings provide a framework for future clinical trials in BCR management.